Using Multiple Imputation to Classify Potential Outcomes Subgroups by Li, Yun et al.
Using Multiple
Imputation to Classify
Potential Outcomes
Subgroups
Journal Title
XX(X):2–32
c©The Author(s) 0000
Reprints and permission:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/ToBeAssigned
www.sagepub.com/
SAGE
Yun Li1,2,3, Irina Bondarenko3, Michael R. Elliott3, Timothy P.
Hofer4,5 and Jeremy M.G. Taylor3
Abstract
With medical tests becoming increasingly available, concerns about over-testing,
over-treatment and health care cost dramatically increase. Hence, it is important
to understand the influence of testing on treatment selection in general practice.
Most statistical methods focus on average effects of testing on treatment decisions.
However, this may be ill-advised, particularly for patient subgroups that tend not to
benefit from such tests. Furthermore, missing data are common, representing large
and often unaddressed threats to the validity of most statistical methods. Finally, it is
often desirable to conduct analyses that can be interpreted causally. Using the Rubin
Causal Model framework, we propose to classify patients into four potential outcomes
subgroups, defined by whether or not a patient’s treatment selection is changed by the
test result and by the direction of how the test result changes treatment selection.
This subgroup classification naturally captures the differential influence of medical
testing on treatment selections for different patients, which can suggest targets to
improve the utilization of medical tests. We can then examine patient characteristics
associated with patient potential outcomes subgroup memberships. We used multiple
imputation methods to simultaneously impute the missing potential outcomes as well
as regular missing values. This approach can also provide estimates of many traditional
causal quantities of interest. We find that explicitly incorporating causal inference
assumptions into the multiple imputation process can improve the precision for some
causal estimates of interest. We also find that bias can occur when the potential
outcomes conditional independence assumption is violated; sensitivity analyses are
proposed to assess the impact of this violation. We applied the proposed methods to
examine the influence of 21-gene assay, the most commonly used genomic test in the
United States, on chemotherapy selection among breast cancer patients.
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Introduction
Newly diagnosed cancer patients and their physicians frequently face the
challenges of deciding which tests and subsequent treatments to use. The testing
itself can be both invasive and expensive, and the cost of medical tests reaches
70 billion dollars annually1. Furthermore, test results do not predictably inform
treatment decisions, either because guidelines are not always available or they
are not followed in practice. Thus, describing how testing impacts the choice
of treatment in general practice is of fundamental importance. We will view this
problem in a causal framework, in which taking the test is the exposure of interest,
and the treatment received is the outcome of interest.
An example is the use of the 21-gene recurrence score (RS) assay in breast
cancer care, the most commonly used genomic assay in the United States. The
test is used to inform recommendations about the use of chemotherapy. Women
who get a high score on the test are recommended to take chemotherapy to reduce
their risk of recurrence, whereas women with a low score are not because they
have a good prognosis and are expected to receive little additional benefit from
chemotherapy. Prior studies have demonstrated that RS tests can provide more
precise estimation of the risk of cancer recurrence and the need for chemotherapy
than do traditional histopathologic features (e.g., tumor grade and size)2–8. Even
though the current clinical guidelines only endorse the use of RS assay in selected
patients with certain clinical characteristics9,10, more and more patients who do
not meet these criteria are being selected for RS testing. Also, chemotherapy is
highly morbid, and many believe it is being over-prescribed11,12. Thus, there is a
pressing need to measure the influence of the RS assay on chemotherapy decisions
to evaluate whether the test is being used in an efficient manner and acted upon
appropriately in general practice.
Determining the influence of testing on treatment selection in a community
practice setting is not well studied and is challenging to quantify using standard
methods. First, selection bias may occur because testing is not offered randomly.
Both clinical factors as well as patient and physician preferences influence
whether testing is offered, and this confounds the effect of testing on treatment
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selection13,14. Second, while causal inference methods such as propensity-score
based methods can address selection bias and give effect estimates with desirable
causal interpretations, they are limited to estimating an overall effect of testing
on treatment selection, not how testing changes treatment plans within patient
subgroups. The overall effect can obscure the degree to which treatment plans
are changed by testing. For example, the overall effect can be zero, if testing
encourages and discourages treatment for an equal number of patients, even
though testing did change treatment plans. Third, missing data are common,
especially when multiple data sources are combined as in many studies. Missing
data are often-unaddressed threats to the validity of statistical methods.
In this paper, we propose to use a potential outcomes framework (i.e., a
causal inference framework)33 to measure the influence of testing by comparing
treatment use when everyone is tested with when no one is tested. This minimizes
selection bias affecting test use that is attributable to observed confounders.
Specifically, we propose to classify patients into four potential outcomes subgroups
defined by their expected treatment decisions with a given test versus without the
test: 1) Never-Treated: those who would not have been treated with or without
the test; 2) Treatment-Encouraged: those who would have been treated with the
test but would not have been treated without the test; 3) Treatment-Discouraged:
those who would not have been treated with the test but would have been treated
without the test; 4) Always-Treated: those who would have been treated with or
without the test. These four subgroups (listed in Table 1) are called potential
outcomes subgroups33. A patients membership in these subgroups may be driven
by patient characteristics or by systemic factors (e.g., treating physician). Such
classification can also suggest ways to improve the utilization of medical tests
in treatment decisions. The classification recognizes that a medical test can have
different influences on treatment decisions for different patients; i.e., there may be
effect heterogeneity of testing on treatment. With the classification, we will be able
to measure how many patients treatment selections are changed (or unchanged) by
test results for overall and key clinical subgroups, and also quantify how much test
results encourage (or discourage) treatment selections. The potential outcomes
subgroups bear some resemblance to principal stratification16, which has been
extensively used by us and others to study the causal effect of intermediate
variables (e.g., degree of compliance, surrogate markers)17–19. However, unlike
principal strata, which are defined by the joint distribution of intermediate
variables under different exposure status, here we focus on the joint distribution of
the outcome of interest (here treatment received) under different exposure status
(here test received). We believe this framework provides important conceptual
and practical advances in studying the influence of medical testing in treatment
selection. We will also demonstrate its advantages of providing unique and highly
relevant causal quantities of interest over alternative causal inference methods.
We will classify patients into these potential outcomes subgroups by exploring
the close connection between missing data analysis and causal inference. Since
two potential outcomes of the same patients are not simultaneously observed,
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we will use multiple imputation methods to impute the unobserved potential
outcomes to enable us to make causal inferences. Multiple imputation methods
have been used to impute missing potential outcomes in solving different problems
in causal inference literature22–25,27,28,30. These methods have the advantage
of simultaneously handling standard missing data in observable variables (e.g.
due to non-response) and missing potential outcomes. However, since missing
data analysis and causal inference have different objectives and data structures,
there are important distinctions between them. First, causal inference focuses on
comparing the potential outcomes of the same patient under different exposure
levels; while missing data analyses do not. Second, the causal assumptions
(e.g., ignorability of treatment assignment or potential outcomes conditional
independence) are not usually made in standard missing data analyses. Third,
causal inference distinguishes pre-exposure variables from post-exposure variables
and usually does not use a post-exposure variable, while missing data analyses do
not differentiate them and often utilize a post-exposure variable in the imputation
models if it is predictive of other variables with missing values. Fourth, the
missing potential outcomes problem is highly structured such that only one of
two potential outcomes is observed for any patient when the exposure variable
is binary. In this situation, the missing data indicator is identical to the binary
exposure variable. Fifth, since no two potential outcomes of the same patient can
be observed simultaneously, there is no information about the correlation between
two potential outcomes of the same patient. This distinct data structure is similar
to the missing data structure in the literature on ”statistical matching”20,21.
More detailed discussions about missing data analyses and causal inference can
be found by Ding and Li (2018) and Westreich et al (2015)29,30. In this paper, we
will study the performance of our proposed methods. We will also examine the
efficiency gain of our causal estimates when we incorporate the knowledge of our
data structure and causal inference assumptions into the multiple imputation
process. We will propose sensitivity analyses to investigate the violation of
one of the key causal inference assumptions on causal estimates (i.e., potential
outcomes conditional independence). Additionally, we will explore the impact of
incorporating a post-exposure variable in the multiple imputation process on the
causal estimates. Furthermore, we will demonstrate that this approach is more
robust towards certain types of model mis-specification than other causal methods
(e.g., propensity-score based methods).
To illustrate our methods, we will examine the impact of the RS assay on the
decision to undergo chemotherapy for breast cancer patients. The analyses will
use combined data sets from the Surveillance, Epidemiology, and End Results
databases (SEER) registry, genomic testing laboratories, and patient/physician
surveys, recently collected from the ICanCare Study31,32. The data linkage was
a unique survey-registry-industry collaboration and the ICanCare study was part
of the only program project funded by National Cancer Institute that focused on
cancer treatment decision making.
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Table 1. Potential outcomes subgroups defined by the effect of testing on treatment
selection.
Treatment Selection with Test (Y1)
Treatment Selection
without Test (Y0) Yes No
Yes Always Treated Treatment Discouraged
No Treatment Encouraged Never Treated
Notation, the Causal Framework and Quantities of Interest
Let Y represent the treatment receipt (i.e., the outcome of interest, 0/1 for
no/yes), Z the status of being tested (i.e., the exposure of interest, 0/1 for no/yes),
X a set of covariates and R the test result. Naturally, R only exists for testers
and is a post-exposure variable. We assume some observations are missing in Y ,
R and in some variables of X. Let M be the associated missing-data indicator
matrix for these observable variables. The observed and missing parts of Y are
denoted by Y obs and Y mis respectively, and the same for X.
For each patient, we assume there are two potential outcomes, Y1 and Y0,
corresponding to being tested or not (Z = 1, 0). Let Y1 indicate a patients
treatment status that would be observed if the patient is tested and Y0 otherwise.
If we know both Y1 and Y0 for every patient, we can infer whether a test
causes a change in treatment selection by comparing Y1 to Y0, and calculate
many causal quantities that are free of selection bias. In this manuscript, we
choose several representative causal quantities including: (1) average testing
effect (ATE), E(Y1 − Y0), for the overall population and patient subgroups; (2)
marginal odds ratio (MOR), [P1(1− P0)]/[P0(1− P1)] where P0 = P (Y0 = 1) and
P1 = P (Y1 = 1); and (3) the fractions of patients in each of the four potential
outcome subgroups: (Y0 = 0, Y1 = 0) for the never-treated, (Y0 = 0, Y1 = 1) for
the treatment-encouraged, (Y0 = 1, Y1 = 0) for the treatment-discouraged, and
(Y0 = 1, Y1 = 1) for the always-treated group, which are denoted by P (00),
P (01), P (10) and P (11) respectively. The MOR defined in (2) compares the
odds of treatment use if everyone were tested to the odds if no one were
tested. Odds ratios in observational studies are usually association measures and
lack causal interpretations because of confounding. In contrast, MORs do have
causal interpretations. Based on the fractions defined in (3), we can calculate
many quantities that are functions of them. For example, we can calculate
the proportion of patients whose treatment plans are changed by the use of
testing (i.e., the proportion of patients who were either treatment encouraged
or discouraged), P (01) + P (10), and the proportion of patients whose treatment
plans are not changed (i.e., the proportion of patients who were either never-
treated or always-treated), P (00) + P (11). In fact, ATE is also a function of these
fractions, which is equal to the difference in the proportions in the “treatment
encouraged” and “treatment discouraged” subgroups, i.e., P (01)− P (10). We are
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also interested in estimating the associations between patient characteristics and
patient membership in these potential outcomes subgroups.
Estimating the Distributions of Potential Treatment Selection
To measure the causal influence of a test, ideally, we wish to know the treatment
plan for each patient when she is tested and when she is not. That is, we wish
to know both Y0 and Y1. However, the treatment plan is observable for a given
patient in only one of these two scenarios because she may not get tested and; even
if she does, her pre-test treatment plan is not usually documented. Formally, this
is a missing data problem. We use sequential regression multiple imputation (or
sometimes called the fully conditional specification method)34,35 to impute the
unobserved (counterfactual) treatment plan for each patient, which we term the
potential outcomes multiple imputation method (POMI). That is, for patients
who received the test, we impute what would have been their treatment plans
had they not received the test. And for patients who did not receive the test, we
impute what would have been their treatment plans had they received the test
from the predictive distribution of Y given X and/or R. Once we have complete
information for Y0 and Y1 after imputation, we can calculate the causal quantities
of interest. Since we have incomplete information in observable variables Y , X
and R, we can simultaneously impute missing potential outcomes and missing
values in these observable variables during the multiple imputation process using
the same imputation methods.
Although we can view causal inference as a missing data problem, there are
distinct features of causal inference different from standard missing data problems.
As stated in the Introduction section, the objectives of causal inference are to
obtain the causal effect of an exposure on the outcome, while missing data analyses
are to handle missing values in variables, utilize incomplete information and
reduce bias due to non-response. Hence, some assumptions are closely related
but others are different. Below we list four assumptions used in missing data
and/or causal inference literature:
1. Missing at random36, f(M |Z, Y,X,R) = f(M |Z, Y obs, Xobs, Robs). That is,
missingness can be explained by the observed data. This is a standard
assumption in the missing data literature. Note that f() denotes a
probability density or mass function for the distribution of either a
continuous or discrete variable in this manuscript.
2. Stable unit treatment value assumption (SUTVA)22,37. The potential
outcomes of one patient are unaffected by the potential outcomes or testing
status of other patients. This is a standard assumption in the causal
inference literature. This assumption is not usually explicitly made, but
it is implied in the missing data literature.
3. Ignorability of exposure38, (Y0, Y1)⊥Z|X. This assumption means that the
receipt of test is “randomized” for subjects with the same set of covariates
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X, that is, there are no unmeasured confounders between Z and Y after
adjustment for X. It is a standard assumption in the causal inference
literature, and a special case of the missing-at-random assumption (see
Assumption 1).
4. Potential outcomes conditional independence, (Y0⊥Y1)|X. This
assumption states that two potential outcomes are conditionally
independent. However, since the two potential outcomes are never observed
together, we have no information about the correlation, independence or
joint distribution of Y0 and Y1 from the observed data. This assumption
is frequently made in the causal inference literature39–41. It is also made
in the missing data and survey methodology literature when applying the
less-known statistical matching technique to conduct a joint analysis on
variables that are never jointly observed20,21. We will explore robustness of
our methods to this conditional independence assumption using sensitivity
analyses.
These assumptions will be essential to facilitating identification and estimation of
causal quantities of interest.
We propose to impute the missing values in X and R as well as the missing
potential outcomes (Y0 and Y1) iteratively variable-by-variable using a sequence
of conditional regression models until convergence: f(Xj |X(−j), Z, Y0, Y1, R),
f(R|X,Z, Y0, Y1), f(Y0|Y1, Z,X,R), f(Y1|Y0, Z,X,R) for any j 34,35,43. Note that
X = (X1, · · · , Xk) and X(−j) = (X1, · · · , X(j−1), X(j+1), · · · , Xk) denoting the
collection of the k − 1 variables in X except Xj . This method is the sequential
regression multiple imputation method and has its advantages in handling non-
normal data34. We can evaluate how well the missing variables are imputed as in
regular missing data imputation problems.
We impute the missing values D times to give a range for each imputed value
to reflect prediction uncertainty. We then obtain the estimates of the quantities
of interest for each of the D imputed data sets before combining these estimates
and their variances across D imputed data sets using Rubin’s formula38. Let ∆
represent any quantity of interest, ∆̂d the point estimate and Wd the within-
imputation variance estimate of ∆̂d for the dth imputed data set. The POMI
estimate of ∆ is obtained by averaging across D imputed data sets, such that
∆ = 1D
∑D
d=1 ∆̂d where d = 1, · · · , D. The MI estimate of the variance of ∆
is V = W + (1 + 1D )B, where W =
∑D
d=1Wd/D, B =
∑D
d=1(∆̂d −∆)2/(D − 1).
Note that W represents the average within-imputation variance and B represents
the between-imputation variance. The estimated ∆ follows a t distribution, with
the degree of freedom (D − 1)[1 + DD+1 (W/B)2]42.
Specifically, the within-imputation variance for the estimated causal
quantity of interest, ATE, for each imputed data set is calculated
as follows: 1N−1
{[
P̂0(1− P̂0)
]
+
[
P̂1(1− P̂1)
]
− 2(P̂11 − P̂0P̂1)
}
, where P11 =
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P (Y0 = 1, Y1 = 1) and N is the sample size. The calculation of the within-
imputation variance of the MOR estimate is more complicated than ATE because
it is a non-linear function of P0 and P1. Since MOR is skewed and positive, we
calculate the variance for the MOR estimate on a log scale. Specifically, for each
imputed data set, we calculate the variance of log(M̂OR) using the delta method
as follows:
[
P̂0 + P̂1 − (P̂0 − P̂1)2 − 2P̂11
]
/
[
NP̂0P̂1(1− P̂0)(1− P̂1)
]
. From the
variance of log(M̂OR), we can then calculate the variance of the estimated
MOR using the delta method again. The details for the variance calculation of
estimated MOR are provided in the appendix. The within-imputation variances
for estimated P (00), P (01), P (11) and P (10) are straightforward to calculate as
multinomial proportions.
What we described so far are standard multiple imputation procedures. We will
explore several features of causal inference that are distinct from standard missing
data problems and see how the incorporation of them in the multiple imputation
process impacts the causal estimates. These features will be incorporated through
the four different POMI methods investigated in the following Simulation
section. First, we will explicitly incorporate the causal inference assumptions
(listed above as Assumptions 2, 3 and 4) and distinct data structures into
the multiple imputations of missing potential outcomes. Under Assumption
2 and 3, we can simplify our imputation models for Y0 and Y1 such that
f(Y0|Y1, Z,X,R) = f(Y0|Y1, X,R) and f(Y1|Y0, Z,X,R) = f(Y1|Y0, X,R). Under
Assumptions 2, 3 and 4, we can further simplify our imputation models for Y0 and
Y1 such that f(Y0|Y1, Z,X,R) = f(Y0|X,R) and f(Y1|Y0, Z,X,R) = f(Y1|X,R).
Considering R only exists for testers, we can further simplify the models such
that f(Y0|Y1, Z,X,R) = f(Y0|X). Second, we will explore the use of Z in the
multiple imputation process. Z is a missing data indicator for Y0 and Y1. With
an MAR assumption, multiple imputation does not need to include the missing
data indicator35. However, here Z also serves the dual role as the exposure of
interest. Third, we will investigate the use of test results R, a correlate of Y
and a post-exposure variable. In causal inference, post-exposure variables are
not usually utilized because they may be in the causal pathway, and adjusting
for them can bias results44. However, in standard missing data problems, post-
exposure variables are usually included in the imputation models to increase the
predictibility of variables with missing values, when post-exposure variables are
correlated with the variables with missing values and hence contain additional
information about them.
Simulations
We conduct simulations to examine: 1) the impact of Z, R and causal inference
assumptions on estimating the quantities of interest through comparisons of
four POMI methods, which differ by whether the imputation models include
Z, and/or R or make certain causal inference assumptions; 2) the properties
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of causal estimates of ATE and MOR estimated by these four POMI methods
and the inverse probability weighting method (IPW); 3) the properties of the
unique causal estimates that are obtainable from the four POMI methods; 4) the
robustness of the POMI methods towards model misspecification in comparisons
with IPW; 5) sensitivity analyses towards the potential outcomes conditional
independence assumption (Assumption 4); 6) the properties of the estimated
association between patient characteristics and potential outcomes subgroup
memberships through the POMI methods.
Simulation Design
We assume that X includes two variables, X1 and X2. The distributions of X1,
X2 and test results R follow a multivariate normal distribution of X1X2
R∗
 ∼MVN
 01
−1
 ,
 1 0.3 0.30.3 1 0.3
0.3 0.3 1
 . (1)
We further categorize R∗ into three groups to mimic the distribution of
RS assay results in our data example. We let R = 1 if R∗ <= −0.747,
R = 2 if −0.747 < R∗ <= 0.282 and R = 3 if R∗ > 0.282. The distributions
of Z, Y0 and Y1 are specified as follows: logit[P (Z = 1)] = −1.5−X1 +
0.5X2 + αX1X2, logit[P (Y0 = 1)] = 0.5X1 +X2 + β1U and logit[P (Y1 = 1)] =
0.5X1 +X2 − 1.5I(R1 = 1)− 0.5I(R1 = 2) + I(R1 = 3) + β2U . Note that U is an
unmeasured predictor of Y , which is used to induce a non-zero correlation between
Y0 and Y1 after adjusting for X and hence a violation of the potential outcomes
conditional independence assumption. We assume U ∼ Normal(0,1). The default
model parameter specifications in our simulations are: α = 0 (i.e., no interaction
between X1 and X2), and β1 = β2 = 0 (i.e., conditional independence between
potential outcomes). However, we will let α 6= 0 when conducting analyses to test
the robustness of our methods towards model misspecifications. We will also allow
β1 and β2 to be non-zero when conducting sensitivity analyses on the potential
outcomes conditional independence assumption (Assumption 4).
Each simulated data set consists of X1, X2, Z, R and Y . To be consistent with
reality, the data set used in the data example does not have information on U ,
or on R when Z = 0. Further, we allow X2 and Y be partially missing. Let Mx
and My be 0 or 1, indicating X2 and Y being available or missing, respectively.
The models for the probability of missing X2 and Y are specified as follows:
logit[P (Mx = 1)] = −1 + 0.2X1 and logit[P (My = 1)] = −2.5 +X1. We assume
X1 is completely measured. For each parameter specification, we simulate 500 data
sets, each of which has N = 1, 000 subjects. Unless specified otherwise, the default
scenarios in our data simulations satisfy Assumptions 1-4. Additional simulations
with N = 500 and 250 subjects are also conducted to assess the impact of different
sample sizes and summarized in Appendix.
We investigate the performance of four POMI methods. These imputation
methods differ by whether the imputation models include Z, R or explicitly
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make causal assumptions of ignorabilty of exposure and potential outcomes
independence (Assumptions 3 and 4). We will investigate the impact of these
choices on estimates of the causal quantities of interest. These choices are reflected
by different conditional regression models as described below. All four methods
make the MAR and SUTVA assumptions (Assumptions 1 and 2), and are carried
out by the IVEWARE software34.
1. Potential outcome imputation method 1 (POMI-Z): this is the
default imputation procedure carried out by IVEWARE which consists
of the following sequence of conditional regression models until
convergence: f(X2|X1, Y0, Y1, R), f(R|X1, X2, Y0, Y1), f(Y0|X1, X2, Y1, R),
and f(Y1|X1, X2, Y0, R). Note that this imputation method does not make
Assumptions 3 and 4, or utilize Z (the exposure variable and the missing
indicator for Y0 and Y1), but it utilizes the post-exposure variable R.
2. Potential outcome imputation method 2 (POMI): different from POMI-Z,
we now include Z in the imputation of missing X2, using the following
sequential regression models: f(X2|X1, Y0, Y1, R, Z), f(R|X1, X2, Y0, Y1),
f(Y0|X1, X2, Y1, R), and f(Y1|X1, X2, Y0, R). The rationale of using the test
status Z in imputing missing X2 is that, the probability of receiving the test
Z is associated with X2; hence, Z contains information about X2. Similar
to POMI-Z, this method does not make Assumptions 3 and 4, but it utilizes
R.
3. Potential outcome imputation method 3 (POMI+IND): different from
POMI, we now incorporate Assumptions 3 and 4, and consider the fact that
test results R are only available among testers. The sequential regression
models are simplified as follows: f(X2|X1, Y0, Y1, R, Z), f(R|X1, Y1, X2),
f(Y0|X1, X2), and f(Y1|X1, X2, R). This is also consistent with the default
setup in our simulations.
4. Potential outcome imputation method 4 (POMI+IND-R): different from
POMI+IND, we now exclude the post-exposure variable R, using the
following sequential regression models: f(X2|X1, Y0, Y1, Z), f(Y0|X1, X2),
and f(Y1|X1, X2).
Note that f(X2|.) represents a conditional probability density function modelled
by a linear regression for X2, f(R|.) represents a conditional probability mass
function modelled by a multinomial regression for R, f(Y0|.) and f(Y1|.) represent
conditional probability mass functions modelled by logistic regression for Y0 and
Y1 respectively. We iteratively impute the missing values in X2, R, Y0 and Y1, with
the sequential conditional regression models until convergence. To evaluate how
well the missing variables are imputed, we compare the distributions of observed
and imputed values conditional on the estimated propensity of being observed45.
We repeat the imputation process 5 times to have 5 imputed data sets. We then
conduct statistical inference on these 5 imputed data sets.
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We compared these four methods with the inverse probability weighting method
(IPW)46 which is a propensity-score based method and commonly used to obtain
causal inference. Before using IPW, we need to address the issue of missing data
first. We use the same sequential regression multiple imputation method to impute
missing values in the observable variables X2 and Y 5 times with the following
sequence of conditional regression models: f(X2|X1, Y, Z), f(Y |X1, X2, Z). For
each of the 5 imputed data sets, we calculate the propensity score (denoted
by pii = P (Zi = 1)) from a logistic regression of Z as a function of X1 and
X2. We then estimate P (Y1 = 1) and P (Y0 = 1) as P̂1,ipw = P̂ipw(Y1 = 1) =(∑N
i
ZiYi
pii
)
/N and P̂0,ipw = P̂ipw(Y0 = 1) =
[∑N
i
(1−Zi)Yi
1−pii
]
/N , respectively.
Hence, the estimated ATE is ÂTEIPW = P̂1,ipw − P̂0,ipw. The marginal odds
ratio is estimated as M̂ORIPW =
[
P̂1,ipw(1− P̂0,ipw)
]
/
[
P̂0,ipw(1− P̂1,ipw)
]
. The
variance calculations of the estimated ATE and MOR use the delta method. For
MOR, the log transformation is used to obtain the variance of log(M̂OR) first
before obtaining the variance of M̂OR, similar to what has been described in the
Appendix. Finally, Rubin’s formulae are used to combine the estimates and their
variances across 5 imputed data sets.
The true values for the causal quantities of interest cannot be obtained
analytically but can be closely approximated by simulating 10 million patients
with complete information on both Y0 and Y1, based on which the true causal
quantities can be obtained. This approach has often been used in causal inference
research. For each set of parameter specifications, we simulate 500 data sets.
For each quantity of interest, we estimate the mean of each estimate, bias (the
difference between the estimate and the true value), coverage probability (CR)
of the 95% confidence interval, standard error (SE), empirical standard deviation
(ESD) and mean squared error (MSE) across 500 data sets.
Simulation Results
First, we evaluate the properties of estimates for ATE and MOR from these
five different methods (Table 2). These quantities of interest are obtainable
from all methods. Based on the evaluation, POMI-Z has larger bias and
lower coverage rates while all other methods give negligible bias and close to
nominal 95% coverage rates. The IPW method tends to give slightly bigger
variance estimates; while all the POMI methods give similar variance estimates.
Additional simulations with N = 500 and 250 show that the bias of the estimates
becomes larger as the sample size decreases in most scenarios; however, they
demonstrate similar patterns across different methods as N=1000 (See Tables
8-11 in Appendix).
Second, we evaluate the properties of the estimated proportions of patients in
each potential outcome subgroup by these five methods (Table 3). We estimate
the fraction of patients that are either never-treated P (00), treatment-encouraged
P (01), treatment-discouraged P (10), or always-treated P (11). Note that IPW
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Table 2. Comparison of five methods in estimating average testing effect (ATE), and
marginal odds ratios (MOR). ESD: empirical standard deviation; SE: average standard
error; CR: coverage rate of 95% confidence interval. Here we assume potential outcomes
conditional independence and no interaction between X1 and X2 (i.e., α = β1 = β2 = 0).
Quantities Methods True 100 × Bias ESD SE 100 × CR
ATE POMI-Z -0.186 1.8 0.032 0.033 90.6
POMI -0.186 0.2 0.033 0.033 94.6
POMI+IND -0.186 0.0 0.032 0.033 94.8
POMI+IND-R -0.186 -0.0 0.032 0.033 95.2
IPW -0.186 0.9 0.035 0.039 96.6
MOR POMI-Z 0.458 4.1 0.070 0.071 90.8
POMI 0.458 0.7 0.067 0.068 94.0
POMI+IND 0.458 0.3 0.065 0.067 94.4
POMI+IND-R 0.458 0.3 0.066 0.067 94.6
IPW 0.458 0.0 0.066 0.074 95.8
cannot provide estimates of these proportions; hence, no estimates from IPW
are provided. The simulation results indicate that POMI+IND and POMI+IND-
R give estimates with smaller bias, smaller ESD and SE than POMI-Z and
POMI. The coverage rates from POMI+IND and POMI+IND-R are also closer
to the nominal 95% coverage rates. Note that the conservative coverage rates
from POMI-Z and POMI result from the variance being severely overestimated,
which overwhelms the bias in these methods. Hence, the results demonstrate the
benefit of taking advantage of the causal assumptions of ignorability and potential
outcomes conditional independence when we estimate the proportions of potential
outcome subgroups. The performances of POMI+IND and POMI+IND-R are
very similar to each other, indicating that there is a minimal advantage in utilizing
the information from the post-exposure variable R to estimate these quantities in
our simulations. Additional simulations with N = 500 and 250 show that the bias
of the estimates becomes larger as the sample size decreases in most scenarios;
however, they demonstrate similar patterns across different methods as N=1000
(See Tables 8-11 in Appendix).
Third, we evaluate the performance of a generalized logit model for potential
outcomes subgroup membership using POMI+IND (Table 4). The model is
specified as log[ P (ij)P (00) ] = γ0ij + γ1ijX2 + γ2ijX1, where ij = 01, 10, or 11 and
γ0ij , γ1ij , γ2ij are the corresponding coefficients. Since POMI+IND demonstrates
advantages over POMI-Z and POMI and similarity as POMI+IND-R in
performance based on prior simulations (Tables 2 and 3), we focus on the
performance of POMI+IND in estimating the coefficients of the generalized
logit model for the potential outcomes subgroup membership. Our simulations
demonstrate that the POMI+IND method performs well in estimating the model
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Table 3. Comparison of five methods in estimating the proportion of patients in each
potential outcome subgroup. ESD: empirical standard deviation; SE: standard error; CR:
coverage rate of 95% confidence interval. Here we assume potential outcomes conditional
independence and no interaction between X1 and X2 (i.e., α = β1 = β2 = 0).
Quantities Methods True 100 × Bias ESD SE 100 × CR
P(00) POMI-Z 0.21 0.15 2.781 4.911 98.6
POMI 0.21 0.40 2.947 4.819 97.6
POMI+IND 0.21 -0.02 1.881 2.057 94.6
POMI+IND-R 0.21 -0.05 1.891 2.058 96.0
IPW – – – – –
P(01) POMI-Z 0.10 1.01 2.449 4.667 98.4
POMI 0.10 0.71 2.454 4.615 98.2
POMI+IND 0.10 0.11 1.386 10..688 95.8
POMI+IND-R 0.10 0.16 1.400 1.695 95.6
IPW – – – – –
P(10) POMI-Z 0.29 -0.85 2.980 5.046 98.6
POMI 0.29 0.45 3.171 4.968 97.0
POMI+IND 0.29 0.08 2.182 2.365 95.2
POMI+IND-R 0.29 0.16 2.174 2.395 95.6
IPW – – – – –
P(11) POMI-Z 0.39 -0.28 2.988 4.971 98.8
POMI 0.39 -0.69 2.908 4.934 98.0
POMI+IND 0.39 -0.17 2.153 2.263 94.4
POMI+IND-R 0.39 -0.26 2.189 2.324 94.8
IPW – – – – –
coefficients with very little bias and their confidence intervals close to nominal
95% coverage rates.
Fourth, we continue to focus on the POMI+IND method and examine the
impact of an unmeasured predictor U of Y on the quantities of interest (Figure
1). The presence of U introduces a correlation between Y0 and Y1 and subsequently
a violation of Assumption 4 (e.g. potential outcome conditional independence).
We let β1 = β2 and vary their sizes to be 0, 0.9, 1.06, 1.2, 1.38 and 1.49,
which correspond to the proportions of variation of Y explained by U being
0%, 5%, 10%, 15%, 20% and 25%, respectively. As the correlations between Y0 and
Y1 increase, the violation of Assumption 4 becomes more severe. Our simulations
show that U has little impact on the bias of ATE and MOR. However, as U
explains more of the variance in Y , Y0 and Y1 become increasingly more correlated;
subsequently, the treatment-encouraged and treatment-discouraged subgroups
become more rare and the bias of the estimated proportion in each potential
outcome subgroup becomes more severe.
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Table 4. Properties of model coefficients from generalized logit model for potential
outcomes subgroup membership using the POMI+IND method. ESD: empirical standard
deviation; SE: standard error; CR: coverage rate of 95% confidence interval. Here we
assume potential outcomes conditional independence and no interaction between X1 and
X2 (i.e., α = β1 = β2 = 0).
Model Parameter True 100 × Bias ESD SE 100 × CR
log[P(01)/P(00)] γ001 -1.052 -0.15 0.233 0.278 95.4
γ101 0.589 -0.74 0.144 0.207 99.4
γ201 1.038 0.08 0.177 0.253 98.6
log[P(10)/P(00)] γ010 0.002 -0.15 0.176 0.208 96.8
γ110 0.498 -2.31 0.174 0.197 96.0
γ210 0.996 -1.70 0.200 0.244 95.6
log[P(11)/P(00)] γ011 -1.059 -0.08 0.295 0.289 93.0
γ111 1.091 -2.79 0.209 0.217 95.4
γ211 2.044 -0.99 0.260 0.288 93.8
Table 5. Comparing the robustness of POMI+IND and IPW towards model
mis-specifications in estimating average testing effect (ATE) and marginal odds ratio
(MOR). ESD: empirical standard deviation; SE: standard error; CR: coverage rate of 95%
confidence interval. Here we assume potential outcomes conditional independence (i.e.,
β1 = β2 = 0) and there is an interaction between X1 and X2 (i.e., α 6= 0).
Quantities True Methods 100 × Bias ESD SE 100 × CR
ATE -0.186 IPW -5.98 0.032 0.036 63.6
-0.186 POMI+IND 0.12 0.032 0.033 95.0
MOR 0.459 IPW -9.18 0.057 0.052 66.0
0.459 POMI+IND 0.65 0.065 0.063 94.0
Lastly, we examine the robustness of the POMI+IND method towards model
misspecification. We compare the method with the IPW method. For IPW to work
properly, the model for the test assignment Z needs to be correctly specified. Here,
we specify the true model for Z as logit[P (Z = 1)] = −1.5−X1 + 0.5X2 + 2X1 ×
X2. However, in data analyses, neither IPW nor POMI+IND methods include the
interaction term X1 ×X2. The simulation results are summarized in Table 5. It
shows that IPW gives biased estimates of ATE and MOR and much below 95%
coverage rates for their confidence intervals; however, the model misspecification
for Z has little impact on estimates from the POMI+IND method. This highlights
the need for IPW to specify correct models for Z; however, this is not required
for the imputation method.
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Figure 1. Relative bias of estimated average testing effect (ATE), marginal odds ratio
(MOR), and proportion of patients in each potential outcomes subgroup, as the variance of
Y explained by an unmeasured predictor of Y , U , increases and subsequently violation of
potential outcomes conditional independence increases (i.e., β1 6= 0 and β2 6= 0). Here we
assume no interaction between X1 and X2 (i.e., α = 0). The true values for ATE is -0.186,
MOR is 0.458 and the proportions of patients in four potential outcomes subgroups,
P (00), P (01), P (10) and P (11), are 0.212, 0.104, 0.290, and 0.394, respectively.
Application: the Impact of the RS Assay on Breast Cancer
Chemotherapy Selection
The analysis data set includes 2,931 incident breast cancer patients in Georgia
and Los Angeles who were diagnosed between 2013-2014 with favorable prognosis
(estrogen positive, human epidermal growth factor receptor 2 negative and
invasive tumor behavior)18,31. These patients were chosen because the RS assay
has the potential to make a difference in their chemotherapy treatment decisions.
The data set comes from three data sources: 1) SEER databases for clinical
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features; 2) patient survey data from the ICanCare study; 3) the RS assay use
and its testing results from the laboratory, Genomic Health, Inc. The outcome
of interest is the receipt of chemotherapy (yes/no). The exposure of interest is
the receipt of the RS assay (yes/no). The covariates include age (year), tumor
grade (1, 2, or 3), tumor size (≤1 cm, 1− 2 cm or ≥2 cm), node status (positive
or negative), the number of major co-morbidities, menopausal status, and the
risk of genetic mutation (low or high), education level (high school or less, some
college, graduate degree), race (White, Black, Latino, Asian, other), insurance
type (medicaid, medicare, private, other) and family income.
Overall, 35% of the patients received the RS assay and 27% received
chemotherapy. Among these RS assay testers, the test results showed that
65%, 27%, and 8% of patients received low-, intermediate- and high-risk scores
respectively. We first fit a logistic regression with above covariates without
addressing missing data. We find that the factors that are significantly associated
with the use of chemotherapy include: the receipt of the RS assay (odds ratio
(OR) = 0.42 with 95% confidence interval (CI): 0.32–0.55), age (OR=0.93, CI:
0.92–0.95), node status (positive vs. negative; OR=7.70, CI: 5.49 – 10.80), tumor
grade (2 vs. 1; OR=2.16, CI: 1.60 – 2.93; 3 vs. 1; OR=14.42, CI: 9.82 – 21.17),
tumor size (1-2 vs. ≤ 1 cm; OR=2.41, CI: 1.72 – 3.36; ≥ 2 vs. ≤ 1 cm; OR=4.48,
CI: 3.09 – 6.48) and the risk of genetic mutation (high vs. low; OR=0.73, CI: 0.54
– 0.99). The C-index from the logistic regression is 0.86. The model was conducted
on 2,022 (69%) patients with complete data. (See Table 12 in Appendix).
We then apply the POMI+IND method to obtain causal estimates. We estimate
that the average causal effect of the RS assay testing on chemotherapy (i.e.,
ATE) is −10% with its 95% CI of (−14%,−7%) and the MOR is 0.59 with
its 95% CI of (0.49, 0.70). Table 6 presents the proportion of patients in each
of the four potential outcome subgroups by overall and by covariates. Overall, it
is estimated that the receipt of the RS assay encouraged a change of treatment
plan in 9%(8%, 11%) of patients from no chemotherapy to chemotherapy, and
20%(17%, 22%) of patients from chemotherapy to no chemotherapy. Hence, the
receipt of RS assay has reduced the overall chemotherapy use by 10% and changed
the treatment plan for a total of 30% of patients. Regardless of whether they were
tested or not, 59% of patients would never receive chemotherapy and 12% would
always receive chemotherapy.
In addition, we find that, independent of the use of the RS assay, older patients
(≥65 years old) are more likely to reject chemotherapy than younger patients (73%
vs. 49% estimated to be in the “never-treatment” subgroup). We also find that,
with the use of the RS assay, patients were more likely to be discouraged from
chemotherapy if they had a larger tumor (36% vs. 19%, 8% in the “treatment-
discouraged” subgroup for patients with tumor size of ≥ 2cm vs. ≤ 1cm, 1-2cm)
or if they had positive nodes (40% vs. 15% for patients with positive vs. negative
nodes). It is particularly noteworthy that even though the guidelines did not make
any recommendations about the use of the RS assay for node-positive patients,
14% of them were offered the RS assay in practice. And in fact these patients were
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more likely to change their chemotherapy plans after testing with the RS assay
than node-negative patients (46% vs. 25% changed for patients with positive vs.
negative nodes).
It is also evident that the RS assay played an influential role in chemotherapy
decisions based on how much the results of the assay changed the treatment
selections: for patients received a low-risk score, 2% were encouraged to receive
chemotherapy vs. 22% discouraged from chemotherapy; for patients received a
high-risk score, 34% were encouraged vs. 5% discouraged. In contrast, for patients
received an intermediate-risk score, 19% were encouraged vs. 17% discouraged.
We also fit a multivariable multinomial logistic regression to examine the
relationship between several key patient clinical predictors and the potential
outcomes subgroup membership. These clinical predictors include tumor node
status, tumor grade, tumor size, and age. They are the most important predictors
for our study population and have been endorsed by the American Joint
Committee on Cancer47. Table 7 listed the estimated probability of patients’
potential outcome subgroup membership as a function of these clinical factors.
We estimate that, for patients with negative node, tumor grade 1, tumor size ≤
1cm, and age<65 years old, there was a 7% chance to be encouraged to receive
chemotherapy and 5% chance to be discouraged from chemotherapy by using the
RS assay, an 88% chance of staying with the decision of no chemotherapy and a
1% of chance of staying with chemotherapy decision regardless of the use of the
RS assay. We also estimate that, for patients with negative node, tumor grade
of 3, tumor size of 1-2cm and age < 65 years old, the chances of changing to
chemotherapy from no chemotherapy, from no chemotherapy to chemotherapy or
staying with chemotherapy or no chemotherapy after the use of the RS assay are
12%, 28%, 52% and 8% respectively. We also found that, generally, patients with
a mix of low-risk factors (e.g., smaller tumor size, lower tumor grade, negative
node) and high-risk factors (e.g., larger tumor size, higher tumor grade, positive
node) for recurrence are more likely to be affected by using the RS assay than
patients with either all low-risk or high-risk factors. For example, node-positive
patients with small and low-grade tumors are most likely to be discouraged from
chemotherapy by using the RS assay. Similarly, node-negative patients with small
but high-grade tumor are most likely to be encouraged to take chemotherapy
by using the RS assay. In contrast, patients with consistently low (high) risk
clinical factors are more likely to remain in the “never treated” (“always treated”)
subgroup.
We further examine how robust our analysis results are towards the violation
of the potential outcomes conditional independence assumption (Assumption 4).
Since Y0 and Y1 are not observed simultaneously in our data, we cannot evaluate
this conditional independence assumption nor estimate the correlation between
Y0 and Y1 based on our data. We artificially induce a correlation by simulating an
additional predictor U of Y that is not in the data set, and examine how sensitive
our analyses are towards the correlation between Y0 and Y1. Since U is a predictor
of Y , U is a common predictor of both Y0 and Y1. Since U is not observed or
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Table 7. Estimated probabilities of potential outcomes subgroup memberships according
to patient clinical characteristics based on multinomial logistic regression
Estimated Probability in Each Subgroup(95%CI)
Tumor Tumor Age Never Treatment Treatment Always
Grade Size (yrs) Treated Encouraged Discouraged Treated
(cm)
Node Status: Negative
1 ≤ 1 ≤ 65 0.88(0.84,0.92) 0.07(0.04,0.10) 0.05(0.02,0.07) 0.01(0.00,0.01)
1 ≤ 1 ≥ 65 0.93(0.90,0.96) 0.06(0.03,0.09) 0.01(0.00,0.02) 0.00(0.00,0.00)
1 1-2 ≤ 65 0.75(0.70,0.80) 0.06(0.03,0.09) 0.17(0.13,0.22) 0.02(0.00,0.03)
1 1-2 ≥ 65 0.92(0.88,0.95) 0.05(0.03,0.08) 0.03(0.01,0.05) 0.00(0.00,0.00)
1 ≥ 2 ≤ 65 0.54(0.43,0.65) 0.04(0.00,0.07) 0.37(0.26,0.47) 0.06(0.01,0.10)
1 ≥ 2 ≥ 65 0.87(0.80,0.94) 0.05(0.00,0.10) 0.07(0.02,0.12) 0.01(0.00,0.02)
2 ≤ 1 ≤ 65 0.75(0.69,0.80) 0.16(0.11,0.20) 0.08(0.04,0.11) 0.02(0.00,0.04)
2 ≤ 1 ≥ 65 0.87(0.82,0.91) 0.10(0.06,0.14) 0.03(0.01,0.05) 0.00(0.00,0.01)
2 1-2 ≤ 65 0.54(0.49,0.60) 0.13(0.09,0.17) 0.25(0.20,0.30) 0.08(0.05,0.10)
2 1-2 ≥ 65 0.83(0.79,0.87) 0.09(0.06,0.12) 0.07(0.04,0.10) 0.01(0.00,0.01)
2 ≥ 2 ≤ 65 0.30(0.23,0.37) 0.10(0.05,0.14) 0.46(0.38,0.53) 0.15(0.09,0.20)
2 ≥ 2 ≥ 65 0.69(0.61,0.76) 0.12(0.07,0.17) 0.17(0.11,0.22) 0.03(0.01,0.05)
3 ≤ 1 ≤ 65 0.29(0.15,0.43) 0.30(0.15,0.45) 0.20(0.07,0.32) 0.21(0.08,0.35)
3 ≤ 1 ≥ 65 0.56(0.41,0.71) 0.30(0.16,0.44) 0.08(0.02,0.16) 0.05(0.00,0.11)
3 1-2 ≤ 65 0.08(0.03,0.12) 0.12(0.07,0.18) 0.28(0.20,0.36) 0.52(0.44,0.61)
3 1-2 ≥ 65 0.38(0.27,0.50) 0.26(0.16,0.36) 0.17(0.09,0.25) 0.18(0.10,0.27)
3 ≥ 2 ≤ 65 0.04(0.01,0.08) 0.07(0.02,0.12) 0.38(0.27,0.48) 0.51(0.40,0.62)
3 ≥ 2 ≥ 65 0.25(0.12,0.38) 0.21(0.10,0.33) 0.25(0.13,0.36) 0.29(0.16,0.42)
Node Status: Positive
1 ≤ 1 ≤ 65 0.40(0.24,0.55) 0.09(0.01,0.17) 0.39(0.23,0.55) 0.13(0.02,0.24)
1 ≤ 1 ≥ 65 0.65(0.48,0.82) 0.11(0.01,0.21) 0.20(0.07,0.33) 0.04(0.00,0.10)
1 1-2 ≤ 65 0.20(0.11,0.29) 0.06(0.01,0.11) 0.61(0.49,0.73) 0.13(0.04,0.21)
1 1-2 ≥ 65 0.56(0.42,0.71) 0.10(0.02,0.18) 0.29(0.16,0.43) 0.04(0.00,0.09)
1 ≥ 2 ≤ 65 0.11(0.04,0.18) 0.03(0.00,0.06) 0.63(0.49,0.77) 0.24(0.11,0.37)
1 ≥ 2 ≥ 65 0.44(0.24,0.63) 0.07(0.00,0.15) 0.37(0.19,0.55) 0.12(0.01,0.26)
2 ≤ 1 ≤ 65 0.23(0.10,0.35) 0.09(0.01,0.17) 0.39(0.23,0.55) 0.30(0.13,0.46)
2 ≤ 1 ≥ 65 0.47(0.29,0.64) 0.09(0.00,0.17) 0.34(0.17,0.50) 0.11(0.01,0.22)
2 1-2 ≤ 65 0.09(0.05,0.14) 0.05(0.02,0.08) 0.51(0.42,0.60) 0.35(0.26,0.43)
2 1-2 ≥ 65 0.34(0.23,0.45) 0.07(0.02,0.13) 0.45(0.34,0.57) 0.13(0.05,0.20)
2 ≥ 2 ≤ 65 0.05(0.02,0.07) 0.03(0.00,0.05) 0.52(0.43,0.61) 0.40(0.31,0.50)
2 ≥ 2 ≥ 65 0.21(0.12,0.30) 0.07(0.02,0.12) 0.49(0.37,0.60) 0.24(0.14,0.33)
3 ≤ 1 ≤ 65 0.03(0.00,0.09) 0.11(0.00,0.25) 0.17(0.01,0.35) 0.69(0.43,0.94)
3 ≤ 1 ≥ 65 0.13(0.00,0.31) 0.18(0.00,0.40) 0.18(0.01,0.38) 0.50(0.19,0.82)
3 1-2 ≤ 65 0.01(0.00,0.02) 0.05(0.00,0.10) 0.16(0.06,0.26) 0.79(0.67,0.90)
3 1-2 ≥ 65 0.06(0.00,0.14) 0.13(0.01,0.25) 0.19(0.06,0.32) 0.61(0.43,0.80)
3 ≥ 2 ≤ 65 0.01(0.00,0.02) 0.04(0.00,0.07) 0.19(0.10,0.28) 0.77(0.67,0.86)
3 ≥ 2 ≥ 65 0.04(0.00,0.09) 0.10(0.01,0.19) 0.18(0.07,0.28) 0.68(0.53,0.83)
Prepared using sagej.cls
20 Journal Title XX(X)
-0.2
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Es
tim
at
es
0 5 10 15 20
% of variance explained by unobserved predictor
Always takersDiscouragedEncouragedNever takers
Always takersDiscouragedEncouragedNever takers
-0.2
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
AT
E 
an
d 
M
O
R
 e
st
im
at
es
0 5 10 15 20
% of variance explained by unobserved predictor
MORATEMORATE
Figure 2. Estimated proportion of patients in each potential outcomes subgroup, ATE and
MOR, as the variance of Y explained by an unmeasured predictor of Y , U , increases and
the subsequent violation of the potential outcomes conditional independence assumption
increases.
adjusted for, this induces the correlation between Y0 and Y1. The more correlated
Y0 and Y1 are, the more severe the violation of the conditional independence
assumption is. We let U = (−0.267 + Y ) ∗ b1 + e, where Y is the observed receipt
of chemotherapy and e ∼ Normal(0, σ2). Since 26.7% of patients were observed
to receive chemotherapy, we choose -0.267 in this equation to ensure that the
mean of U equals 0. We vary b1 to change the association between U and Y and
examine how it affects the causal estimates. For each b1 value, we re-impute the
missing values conditional on the same set of covariates listed previously and the
simulated predictor U , and then re-estimate the causal quantities of interest using
the POMI+IND method. Figure 2 plots the estimates according to a wide range
of the extent of variation in Y explained by U , which is estimated by a non-linear
mixed effect model with U as a random effect48. As the extent of variation in Y
explained by U increases, the proportions of patients in the “never treated” and
“always treated” subgroups increase, and the proportions in other two subgroups
decrease. Subsequently, the overall influence of 21-gene assay on chemotherapy
receipts decreases. We also observe that MOR and ATE only increase slightly.
Overall, these causal estimates are not very sensitive towards U .
Discussion
We proposed a potential outcomes framework to measure the influence of medical
testing on treatment selection, stratifying patients into four potential outcomes
subgroups based on whether the test has any impact on treatments election (either
undergoing the treatment or not), and whether the test encourages or discourages
treatment selection. This framework captures well the differential causal effect of
testing on treatment selection for different patient subgroups, and allows us to
examine the distribution of these subgroups and characteristics associated with
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these subgroup memberships. The classification suggests targets for more efficient
utilization of medical tests. With advanced tests designed to support precision
medicine becoming increasingly available and increasing concern for over-testing3,
the causal estimates produced from this framework become more relevant. The
framework also allows us to estimate many traditional causal quantities of interest
(e.g., average causal effects, marginal odds ratios) on which existing causal
inference methods more often focus. By taking advantage of the connection
between missing data and causal inference, we can simultaneously implement the
causal framework as well as handle missing data in the observable variables (i.e.,
due to non-response). We also explore the advantages of incorporating unique
features of causal inference assumptions in the data imputation process. These
assumptions are often made in causal inference literature, but cannot be estimated
or verified from the data. Simulation studies suggested that the proposed methods
provide reasonably accurate inference. Additionally, the explicit incorporation of
the causal assumptions in the data imputation process can improve precision for
some causal estimates. We also find that bias can occur for some causal estimates
when the potential outcomes conditional independence assumption is violated,
which can be assessed through sensitivity analyses. The proposed framework was
then used to examine how the most commonly used genomic test in the United
States, 21-gene assay, impacts the use of chemotherapy among breast cancer
patients.
Existing research has often focused on estimating the overall relationship
between medical testing and treatment options in a population. For example,
breast magnetic resonance imaging has been found to be associated with receiving
a mastectomy instead of breast conserving surgery (adjusted odds ratio =
1.21)49. In another example, it is found that 55% of women with invasive
breast cancer and positive HER2 genetic testing results received trastuzumab
treatment50. Although this information is of interest, the average effect of testing
on treatment choice may not apply equally across subgroups of patients who
may not benefit from (or, may be harmed by) testing. Hence, it is important
to recognize that a medical test can have different influences on treatment
decisions for different patients; i.e., there may be effect heterogeneity of testing
on treatment. We proposed the use of potential outcomes subgroups to classify
patients by the presence (vs. absence) and direction of the effect of testing on
treatment decisions. Patients are classified into one of the four groups: 1) never
treated; 2) treatment encouraged; 3) treatment discouraged; 4) always treated.
These subgroups naturally capture the effect heterogeneity of medical testing on
treatment decisions. Additionally, we investigated how patients’ membership in
these subgroups may be driven by patient characteristics or systemic factors. Such
classification would suggest targets for improving the utilization of medical tests
and the allocation of limited resources. For example, in the data analyses, we found
that patients with positive nodes were more influenced by the testing and more of
these patients were discouraged from receiving chemotherapy than patients with
negative nodes, even though guidelines make no recommendations for how to use
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the 21-gene assay in node-positive patients. We also find that patients with a
mix of low and high risk factors were more likely to be influenced by the use of
21-gene assay, and the tests were more likely to either encourage or discourage
these patients for chemotherapy use. Given that the test was recommended to aid
decision-making in people with intermediate risk of recurrence, our results show
that efforts to ensure that the patients with a mix of low and high risk factors are
offered testing are likely to produce substantial changes in plans and maximize
the utility of the test.
Our methods differ from traditional latent class models, which usually deal
with multiple or longitudinal outcomes and do not classify patients by potential
outcomes. Subgroup analysis or adding interaction terms can also investigate
effect heterogeneity; however, these approaches require us to pre-specify variables
that modify effect and suffer from false discovery rate51. In summary, standard
analyses cannot provide the classification targeted by our methods. Our methods
of analyzing heterogeneous testing effect using the potential outcomes subgroups
approach are at the individual level. For each patient, the testing effect on
treatment is obtained by comparing her underlying tendency of receiving
treatment with vs. without a given test. Our approach may be complementary
to the standard analyses based on known effect modifiers. Further discussions of
individual heterogeneous treatment effects are discussed by others39,52,53.
We proposed the use of multiple imputation methods to impute the missing
potential outcomes for each patient (Y0 or Y1) since we do not observe two
potential outcomes of the same patient simultaneously. Subsequently, we can
classify patients into four potential outcomes subgroups according to individual
heterogeneous treatment effects. We chose the sequential regression multiple
imputation method. It has the advantages of accommodating many different data
types and structure compared with other missing data methods54. The main
uncertainty in theoretical justification for this method is the likely incompatibility
between the assumed conditional models and the true conditional models derived
from the joint conditional distributions34. However, many simulation studies have
demonstrated the robustness of this method towards possible misspecifications of
the assumed conditional models54.
Our methods have the advantage of imputing missing potential outcomes and
regular missing values in the observable variables simultaneously during the data
imputation process. This is more convenient and faster than most of other causal
inference methods in the presence of missing data, which will likely need to handle
the missing data problem first using multiple imputation methods before applying
causal inference methods and combining analysis results across multiple imputed
data sets.
The use of multiple imputation methods utilizes the close connection between
causal inference and missing data framework, since the causal inference problems
here are essentially a missing data problem. However, there are some unique
features of causal inference that are different from the regular missing data
problems in our context. First, causal assumptions are unique. Even though there
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is no information from the data to test the validity of the assumptions regarding
ignorability or potential outcomes conditional independence, we demonstrate that
the explicit incorporation of these causal assumptions into the data imputation
process can increase the precision of some of our causal estimates such as the
proportion of patients in each of the potential outcomes subgroups. Second,
we find that the violation of the potential outcomes conditional independence
assumption does not have much impact on traditional causal quantities such as
the average causal effect or marginal odds ratio. However, it does impact the
causal quantities regarding the potential outcomes subgroups, which concern
the joint distribution of the potential outcomes. As the correlation between
two potential outcomes increases, patients in the treatment-encouraged and
treatment-discouraged subgroups become fewer. Since there is no information
from the empirical data about the validity of this assumption, we proposed a
method to conduct sensitivity analyses to relax this assumption and evaluate
the impact of violation of this assumption. Our proposed sensitivity analyses are
closely related to the random effect models proposed by Zhang et al.39, which
use random effects to induce the correlation between Y0 and Y1. Here we used an
unmeasured predictor of Y to induce the correlation. Third, Z is the missing data
indicator for Y0 and Y1. With an MAR assumption, multiple imputation does not
usually need to include the missing indicator35. However, Z is also the exposure
of interest. And it is a function of the covariate X2, which is partially missing.
Hence, for multiple imputation of X2 to work properly, the imputation model for
X2 needs to include Z to satisfy the MAR assumption. This explains why POMI-
Z performs more poorly in our simulations compared with methods including Z
in the imputation models. Fourth, a post-exposure variable (e.g., testing results)
that is correlated with the outcome is not usually utilized in the causal inference
methods because it can be in the causal pathway between the exposure and
outcome. However, it is usually used in the multiple imputation process and not
treated differently from other variables. Our study finds that the incorporation
of a post-exposure variable in the multiple imputation process still generates
valid causal estimates. In fact, it did not make much difference whether or not
we included the post-exposure variable in our simulations. However, we believe
that if the post-exposure variable is correlated with variables that have more
missingness, the utilization of the post-exposure variable will increase precision.
In our simulations, there is only 10% missingness in the variable Y , a correlate
of the post-exposure variable R; hence, the incorporation of R in the imputation
process did not provide noticeable efficiency gain. Lastly, we find that our POMI
methods do not require the need to correctly specify the model for the exposure
to obtain valid causal estimates; however, a propensity-score based causal method
usually does. This feature occurs because the POMI methods do not require one
to model the exposure but only to provide a correct predictive model for the
outcome. Our methods can be implemented through IVEware in SAS, or through
the MICE (Multivariate Imputation by Chained Equations) package in R. We have
provided code examples in GitHub at https://github.com/yunliyunli/POMI.
Prepared using sagej.cls
24 Journal Title XX(X)
In summary, we proposed a potential outcomes framework to classify patients
according to the differential causal effect of medical testing on treatment selection
for different individual patients. It has the potential to be very useful in examining
effect heterogeneity of medical testing on treatment selection and in proposing
targets for the optimal use of medical tests. Future research includes conducting
more sensitivity analyses on the causal assumptions and improving the efficiency
for these causal quantities of interest.
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Table 8. Additional simulations: comparison of five methods in estimating average testing
effect (ATE), and marginal odds ratios (MOR) when N=250. ESD: empirical standard
deviation; SE: average standard error; CR: coverage rate of 95% confidence interval. Here
we assume potential outcomes conditional independence and no interaction between X1
and X2 (i.e., α = β1 = β2 = 0).
Quantities Methods True 100 × Bias ESD SE 100 × CR
ATE POMI-Z -0.186 2.9 0.071 0.076 93.2
POMI -0.186 1.6 0.070 0.082 94
POMI+IND -0.186 0.8 0.068 0.066 91.4
POMI+IND-R -0.186 0.6 0.066 0.066 92.4
IPW -0.186 -0.5 0.074 0.077 93.8
MOR POMI-Z 0.458 7.7 0.169 0.187 91.8
POMI 0.458 4.7 0.161 0.192 95.6
POMI+IND 0.458 3.1 0.147 0.141 90.6
POMI+IND-R 0.458 2.4 0.143 0.141 92.8
IPW 0.458 2.1 0.146 0.156 93.6
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Appendix
Additional Simulation Results with Different Sample Sizes
Additional simulations were conducted using a sample size of 250 to evaluate the
impact of sample size. Results are summarized in Tables 8-9.
Additional simulations were conducted using a sample size of 500 to evaluate
the impact of sample size. Results are summarized in Tables 10-11.
Logistic regression Results for Chemotherapy Use
The results from the logistic regression model are presented in Table 12.
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Table 9. Additional simulation: comparison of five methods in estimating the proportion of
patients in each potential outcome subgroup when N=250. ESD: empirical standard
deviation; SE: standard error; CR: coverage rate of 95% confidence interval. Here we
assume potential outcomes conditional independence and no interaction between X1 and
X2 (i.e., α = β1 = β2 = 0).
Quantities Methods True 100 × Bias ESD SE 100 × CR
P(00) POMI-Z 0.21 0.49 5.527 7.529 94.4
POMI 0.21 0.44 4.703 7.934 98.2
POMI+IND 0.21 -0.27 3.576 4.046 95.4
POMI+IND-R 0.21 -0.27 3.654 4.063 95.2
IPW – – – – –
P(01) POMI-Z 0.10 3.08 4.737 6.978 91.6
POMI 0.10 2.82 3.965 7.391 98
POMI+IND 0.10 0.60 2.933 3.368 95
POMI+IND-R 0.10 0.51 2.839 3.383 95.8
IPW – – – – –
P(10) POMI-Z 0.29 -1.11 6.328 8.268 94
POMI 0.29 -0.45 5.724 8.988 98.4
POMI+IND 0.29 -0.24 4.511 4.700 93.2
POMI+IND-R 0.29 -0.04 4.438 4.712 94.2
IPW – – – – –
P(11) POMI-Z 0.39 -0.43 6.261 8.080 95.4
POMI 0.39 -0.39 5.211 8.865 99.4
POMI+IND 0.39 -0.08 4.073 4.689 96.8
POMI+IND-R 0.39 -0.20 4.001 4.670 96.2
IPW – – – – –
Table 10. Additional simulation: comparison of five methods in estimating average testing
effect (ATE), and marginal odds ratios (MOR) when N=500. ESD: empirical standard
deviation; SE: average standard error; CR: coverage rate of 95% confidence interval. Here
we assume potential outcomes conditional independence and no interaction between X1
and X2 (i.e., α = β1 = β2 = 0).
Quantities Methods True 100 × Bias ESD SE 100 × CR
ATE POMI-Z -0.186 2.0 0.048 0.047 90.6
POMI -0.186 0.4 0.047 0.050 93.8
POMI+IND -0.186 0.1 0.048 0.047 91.6
POMI+IND-R -0.186 0.1 0.049 0.047 92
IPW -0.186 -0.9 0.052 0.054 96
MOR POMI-Z 0.458 4.8 0.110 0.105 90.2
POMI 0.458 1.6 0.099 0.104 94.2
POMI+IND 0.458 0.9 0.101 0.096 91.6
POMI+IND-R 0.458 0.8 0.100 0.096 92.6
IPW 0.458 0.4 0.101 0.106 95.2
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Table 11. Additional simulation: comparison of five methods in estimating the proportion
of patients in each potential outcome subgroup when N=500. ESD: empirical standard
deviation; SE: standard error; CR: coverage rate of 95% confidence interval. Here we
assume potential outcomes conditional independence and no interaction between X1 and
X2 (i.e., α = β1 = β2 = 0).
Quantities Methods True 100 × Bias ESD SE 100 × CR
P(00) POMI-Z 0.21 0.34 4.315 5.948 96
POMI 0.21 0.03 3.737 6.154 97.4
POMI+IND 0.21 -0.07 2.734 2.863 93.8
POMI+IND-R 0.21 -0.07 2.777 2.925 93.2
IPW – – – – –
P(01) POMI-Z 0.10 1.50 1.501 0.954 95.4
POMI 0.10 0.96 0.963 0.976 97.6
POMI+IND 0.10 0.23 0.228 0.954 95.4
POMI+IND-R 0.10 0.29 0.291 0.962 96.2
IPW – – – – –
P(10) POMI-Z 0.29 -0.84 4.522 6.278 95.2
POMI 0.29 0.11 4.167 6.523 98.6
POMI+IND 0.29 0.14 3.289 3.357 93.2
POMI+IND-R 0.29 0.23 3.303 3.387 93.4
IPW – – – – –
P(11) POMI-Z 0.39 -0.47 4.231 6.325 98
POMI 0.39 -0.59 3.934 6.312 99
POMI+IND 0.39 -0.30 2.928 3.296 95.6
POMI+IND-R 0.39 -0.45 2.911 3.302 96
IPW – – – – –
Variance Estimates of Marginal Odds Ratio
The MOR is defined as MOR= [P1/(1− P1)]/[P0/(1− P0)]. Since MOR is skewed
and bounded to be positive, we use log transformation to make it more symmetric
so that we can use the delta method to obtain the variance estimate of log(M̂OR)
first. Let log(M̂OR)d be the point estimate of log(MOR) in the dth imputed data
set where d = 1, . . . D. The combined multiple imputation estimate of log(MOR)
across D imputed data sets is
log(M̂OR) =
1
D
D∑
d=1
log(M̂OR)d.
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Table 12. Logistic Regression Results for Chemotherapy Use Based on Observed Variables.
RS Assay: 21-Gene Assay
Variable Categories OR 95% CI
Receipt of RS Assay Yes vs. No 0.42 0.32 0.55
Tumor grade 2 2.16 1.60 2.93
(Ref: 1) 3 14.42 9.82 21.17
Age (year) 0.93 0.92 0.95
Tumor size (cm) 1− 2 2.41 1.72 3.36
(Ref: ≤1) ≥ 2 4.48 3.09 6.48
Positive Node Status Yes vs. No 7.70 5.49 10.80
High Risk of Genetic Mutation Yes vs. No 0.73 0.54 0.99
Number of Comorbidities 1.04 0.84 1.28
Race Black 1.05 0.73 1.51
(Ref: White) Latino 0.73 0.50 1.07
Asian 0.77 0.47 1.24
Other 1.12 0.35 3.58
Education Some college 0.87 0.60 1.26
(Ref: High school or less) Graduate 0.90 0.61 1.32
Family Income 1.02 0.94 1.11
Insurance None 0.78 0.19 3.25
(Ref: Private) Medicaid 1.39 0.87 2.23
Medicare 0.92 0.62 1.36
Other 1.56 0.44 5.51
For the variance of log(M̂OR) in the dth imputed data set denoted by Wd, we
calculate it using the delta method as below:
[
∂log(M̂OR)
∂p1
∂log(M̂OR)
∂p0
]
× V ar(p̂1, p̂0)×
∂log(M̂OR)∂p1
∂log(M̂OR)
∂p0

=
1
N
[
1
p̂1(1−p̂1)
−1
p̂0(1−p̂0)
]
×
[
p̂1(1− p̂1) p̂11 − p̂0p̂1
p̂11 − p̂0p̂1 p̂0(1− p̂0)
]
×
[
1
p̂1(1−p̂1)−1
p̂0(1−p̂0)
]
=
p̂0 + p̂1 − (p̂0 − p̂1)2 − 2p̂11
Np̂0p̂1(1− p̂0)(1− p̂1) (2)
Averaging over multiple imputed data sets, we calculate the average within-
imputation variance as W =
∑D
d=1Wd/D. For between-imputation variance
denoted by B, we have B =
∑D
d=1
[
log(M̂OR)d − log(M̂OR)
]2
/(D − 1). The
multiple imputation estimate of the variance of log(M̂OR) is V = W + (1 + 1D )B.
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After we obtain the variance of the estimated log(MOR), we can then use the
delta method to obtain the variance of estimated MOR such that V ar(M̂OR) =
exp
{
2
[
log(M̂OR)
]}
× V ar
[
log(M̂OR)
]
.
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